Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

marketwatch.com - Kubota Pharma FY Loss Y676.00M Vs Loss Y1.33B
Kubota Pharma FY Loss Y676.00M Vs Loss Y1.33B
MarketWatch

Kubota Pharmaceutical Holdings Co. Ltd. (4596.TO) Japan Year Ended December 31 GROUP 2025 2024 Revenue Y21.00 mln Y27.00 mln Operating Profit (Y895.00 mln) (Y1.35 bln) Pretax Profit (Y676.00 mln) (Y1.33 bln) Net Profit (Y676.00 mln) (Y1.33 bln) Per…

fortune.com - Annette Bakker - The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients
The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients
Fortune

For patients living with rare and neglected diseases, the next breakthrough treatment might already be sitting in a pharmaceutical company's filing cabinet. Pfizer once shelved an experimental cancer drug. Then the Children's Tumor Foundation came…

news-medical.net - LGM Pharma expands U.S. manufacturing, bringing total investment to $15M across Texas and Colorado sites
LGM Pharma expands U.S. manufacturing, bringing total investment to $15M across Texas and Colorado sites
News-Medical

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to its…

marketbeat.com - Innate Pharma (IPHA) Projected to Post Earnings on Thursday
Innate Pharma (IPHA) Projected to Post Earnings on Thursday
MarketBeat

Innate Pharma (NASDAQ:IPHA - Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Innate Pharma to post earnings of ($0.3492) per share and revenue of $1.96 million for the…

globenewswire.com - Roquette Frères - Roquette's 2025 results show the resilience of its expanded portfolio in a very difficult market environment
Roquette's 2025 results show the resilience of its expanded portfolio in a very difficult market environment
GlobeNewswire

Roquette's 2025 results show the resilience of its expanded portfolio in a very difficult market environment The Group's strategy and recent acquisitions enable upselling to higher-value markets +8% turnover growth to €4.9 billion (-5%…

marketbeat.com - Innate Pharma (IPHYF) Expected to Announce Quarterly Earnings on Thursday
Innate Pharma (IPHYF) Expected to Announce Quarterly Earnings on Thursday
MarketBeat

Innate Pharma (OTCMKTS:IPHYF - Get Free Report) is expected to be posting its results before the market opens on Thursday, March 26th. Analysts expect Innate Pharma to post earnings of ($0.3524) per share and revenue of $1.96 million for the…

adweek.com - Richard Lowe - How Healthcare Marketers Can Navigate Immense Data
How Healthcare Marketers Can Navigate Immense Data
ADWEEK

This post was created in partnership with PulsePoint For healthcare marketers, can too much data be a bad thing? And what are the best practices for navigating privacy regulations? During an ADWEEK House Austin panel co-hosted with PulsePoint…

swissinfo.ch - swissinfo.ch - Economists predict a weak economic year for Switzerland
Economists predict a weak economic year for Switzerland
www.swissinfo.ch

The Swiss Economic Institute (KOF) at the federal technology institute ETH Zurich is also forecasting growth of 1%, but only if oil prices fall again soon. If oil prices remain at current levels for a longer period, growth of just 0.7% is expected…

statnews.com - Elaine Chen - Eli Lilly's 'triple-G' drug leads to significant blood sugar, weight reductions in diabetes trial
Eli Lilly's 'triple-G' drug leads to significant blood sugar, weight reductions in diabetes trial
STAT

Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study, a notable result given that people with diabetes usually don't lose as much weight on treatments as…

prweb.com - Moon Rabbit - Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director
Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director
PRWeb

Before joining Moon Rabbit, Levinson served as head of strategy at Wildtype Health, where she oversaw key oncology initiatives including Merck's Keytruda, and previously held senior strategy positions with McCann Health Network, Grey Group, and…

fool.com - Adria Cimino - 2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow
2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow
The Motley Fool

Johnson & Johnson (JNJ 0.35%) reached a transition point a few years ago. The company spun off its consumer health business into Kenvue in order to shift its focus and financial resources to its innovative medicine and medtech businesses. J&J did…

boston.com - Annie Jonas - Here's how much a remote per diem worker makes north of Boston
Here's how much a remote per diem worker makes north of Boston
Boston.com

What is it like to live and/or work in one of the country's most expensive cities? We asked, and you answered. Greater Boston's economy is powered by workers from across industries, pay ranges, and job types: from baristas to software engineers…

newstatesman.com - Luke O’Reilly - Trump and Mamdani see two different Irelands
Trump and Mamdani see two different Irelands
The Newstatesman

The scene was familiar: Donald Trump received his guest in the Oval Office, Kublai Khan style. The media gathered around, cameras flashing. The guest needed something from him, or depended on him in some way – they always do, it's America.

thehindubusinessline.com - Novo Nordisk's semaglutide patent expiry on Friday - lower-cost generics poised for launch on Saturday
Novo Nordisk's semaglutide patent expiry on Friday - lower-cost generics poised for launch on Saturday
BusinessLine

The high-profile obesity and diabetes products Wegovy and Ozempic, from Danish healthcare company Novo Nordisk, will see a significant global development on Friday — as a patent on its active ingredient semaglutide expires in countries…

republicworld.com - Shourya Jha - Dalal Street Meltdown: Sensex Tanks 1,850 Pts as Banking Crisis and $111 Oil Trigger All-Sector Rout
Dalal Street Meltdown: Sensex Tanks 1,850 Pts as Banking Crisis and $111 Oil Trigger All-Sector Rout
Republic World

The carnage on Dalal Street intensified by mid-morning on Thursday, as a leadership crisis at HDFC Bank evolved into a broad-based market rout. While banking remains the epicenter, high-growth sectors like IT and heavyweights like Larsen & Toubro…

Receive a Daily briefing on Pharma Industry News

Get Started